IDRA Key Statistics, Chart & Performance
The current stock price of IDRA is 0.425 USD. In the past month the price increased by 54.55%. In the past year, price decreased by -28.08%.
IDRA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IDRA. When comparing the yearly performance of all stocks, IDRA is a bad performer in the overall market: 74.57% of all stocks are doing better.
IDRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IDRA. Both the profitability and financial health of IDRA have multiple concerns.
IDRA Financial Highlights
Over the last trailing twelve months IDRA reported a non-GAAP Earnings per Share(EPS) of 2.34. The EPS increased by 160.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
IDRA Forecast & Estimates
IDRA Ownership
About IDRA
Company Profile
Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101. The company is also focused on rare, orphan pulmonary and rheumatic diseases.
Company Info
IDERA PHARMACEUTICALS INC
505 Eagleview Boulevard, Suite 212
Exton PENNSYLVANIA 19341 US
CEO: Vincent J. Milano
Employees: 13
Phone: 14843481600.0
IDERA PHARMACEUTICALS INC / IDRA FAQ
What does IDRA do?
Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101. The company is also focused on rare, orphan pulmonary and rheumatic diseases.
What is the stock price of IDERA PHARMACEUTICALS INC today?
The current stock price of IDRA is 0.425 USD. The price decreased by -21.57% in the last trading session.
Does IDRA stock pay dividends?
IDRA does not pay a dividend.
How is the ChartMill rating for IDERA PHARMACEUTICALS INC?
IDRA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of IDRA stock?
IDERA PHARMACEUTICALS INC (IDRA) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of IDERA PHARMACEUTICALS INC (IDRA)?
The PE ratio for IDERA PHARMACEUTICALS INC (IDRA) is 0.18. This is based on the reported non-GAAP earnings per share of 2.34 and the current share price of 0.425 USD.
Should I buy IDRA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IDRA.